Edgar Filing: BIOCRYST PHARMACEUTICALS INC - Form 3

BIOCRYST PHARMACEUTICALS INC

Form 3

August 26, 2013

FORM 3

(Print or Type Responses)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF

OMB APPROVAL

OMB Number:

3235-0104

Expires:

January 31, 2005

0.5

Estimated average burden hours per

response...

SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting 2. Date of Event Requiring 3. Issuer Name and Ticker or Trading Symbol Person * Statement BIOCRYST PHARMACEUTICALS INC [BCRX] Barnes Alane P (Month/Day/Year) 07/26/2013 (Last) (First) (Middle) 4. Relationship of Reporting 5. If Amendment, Date Original Person(s) to Issuer Filed(Month/Day/Year) 1929 BRASSFIELD ROAD (Check all applicable) (Street) 6. Individual or Joint/Group Filing(Check Applicable Line) 10% Owner Director _X_ Form filed by One Reporting _X__ Officer Other Person RALEIGH, ÂNCÂ 27614 (give title below) (specify below) Form filed by More than One VP, General Counsel & Corp Sec Reporting Person (City) (State) (Zip) Table I - Non-Derivative Securities Beneficially Owned 2. Amount of Securities 4. Nature of Indirect Beneficial 1. Title of Security Beneficially Owned Ownership Ownership (Instr. 4) (Instr. 4) Form: (Instr. 5) Direct (D) or Indirect (I) (Instr. 5) D Â Common Stock 41,931 Reminder: Report on a separate line for each class of securities beneficially SEC 1473 (7-02) owned directly or indirectly. Persons who respond to the collection of

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security		4. Conversion or Exercise	5. Ownership Form of	6. Nature of Indirect Beneficial Ownership	
			(Instr. 4)		Price of	Derivative	(Instr. 5)	
	Data Essentiable I	Expiration Date	Title	Amount or Number of	Derivative	Security:		
					Security	Direct (D)		
						or Indirect		

Edgar Filing: BIOCRYST PHARMACEUTICALS INC - Form 3

				Shares		(I) (Instr. 5)	
Emp. Stock Option (Right to Buy)	09/18/2007(1)	09/18/2016	Common Stock	10,000	\$ 9.95	D	Â
Emp. Stock Option (Right to Buy)	05/16/2008(1)	05/16/2017	Common Stock	3,512	\$ 7.98	D	Â
Emp. Stock Option (Right to Buy)	03/14/2009(1)	03/14/2018	Common Stock	6,709	\$ 3.26	D	Â
Emp. Stock Option (Right to Buy)	03/02/2010(1)	03/02/2019	Common Stock	13,500	\$ 1.2	D	Â
Emp. Stock Option (Right to Buy)	03/01/2011(1)	03/01/2020	Common Stock	42,000	\$ 6.68	D	Â
Emp. Stock Option (Right to Buy)	03/01/2012(2)	03/01/2021	Common Stock	30,000	\$ 4.15	D	Â
Emp. Stock Option (Right to Buy)	03/01/2013(2)	03/01/2022	Common Stock	50,000	\$ 4.73	D	Â
Emp. Stock Option (Right to Buy)	01/01/2014(3)	01/01/2023	Common Stock	100,000	\$ 1.42	D	Â

Reporting Owners

Reporting Owner Name / Address	Relationships				
	Director	10% Owner	Officer	Other	
Barnes Alane P 1929 BRASSFIELD ROAD RALEIGH, NC 27614	Â	Â	VP, General Counsel & Corp Sec	Â	

Signatures

/s/ Alane P.
Barnes

**Signature of Reporting Person

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 5(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- Options become exercisable at the rate of 25% after 1 year and then 1/48 per month thereafter until fully vested and exercisable after 48 months.
- (2) Options become exercisable at a rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant.
- 50,000 Annual Employee Stock Options become exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant. 50,000 Retention Stock Options become exercisbale at the rate of 50% on each of the first and second anniversaries of the date of grant.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Reporting Owners 2